[1] 中国抗癌协会肿瘤整体评估专业委员会,刘波.阿片类药物不良反应综合防治专家共识(2024年版)[J].中国肿瘤临床,2024,51(15):757-763.
[2] WHO Guidelines for the Pharmacological
and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents[M].
World Health Organization, 2018.
[3] 倪嘉淳,蔡增进,江琼,等.药物治疗阿片类药物所致便秘的研究进展[J].中国全科医学, 2022, 25(12) : 1499-1505.
[4] KETWAROO G A, CHENG V,
LEMBO A. Opioid-induced bowel dysfunction[J/OL]. Current Gastroenterology
Reports, 2013, 15(9): 344. DOI:10.1007/s11894-013-0344-2.
[5] KIM E S. Oxycodone/naloxone
prolonged release: A review in severe chronic pain[J/OL]. Clinical Drug
Investigation, 2017, 37(12): 1191-1201. DOI:10.1007/s40261-017-0593-1.
[6] KALSOE, EDWARDSJ E, MOOREA
R, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and
safety[J]. Pain,2004,112(3): 372-380.
[7] 沈波,杨扬,申文,等.江苏省成人癌症疼痛诊疗规范(2020年版)[J].中国肿瘤临床, 2020, 47(7): 325-333,
1-18.
[8] MARUYAMA M, MIIDA S, SATO
T, et al. Effectiveness and safety of lubiprostone after switching from
stimulant laxatives in elderly patients with chronic constipation[J/OL]. JGH
Open, 2023, 7(9): 610-617. DOI:10.1002/jgh3.12956.
[9] WANG D, DU Y, HUANG S, et
al. Combined supplementation of sodium humate and glutamine reduced diarrhea
incidence of weaned calves by intestinal microbiota and metabolites
changes[J/OL]. Journal of Animal Science, 2021, 99(11): skab305.
DOI:10.1093/jas/skab305.
[10] YANG Z, WEI C, LI X, et al.
Association between regular laxative use and incident dementia in UK biobank
participants[J/OL]. Neurology, 2023, 100(16)[2025-03-20].
https://www.neurology.org/doi/10.1212/WNL.0000000000207081.
DOI:10.1212/WNL.0000000000207081.
[11] DUPOIRON D, STACHOWIAK A,
LOEWENSTEIN O, et al. A phase III randomized controlled study on the efficacy
and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg
daily) vs oxycodone PR[J/OL]. European Journal of Pain, 2017, 21(9): 1528-1537.
DOI:10.1002/ejp.1054.
[12] DUPOIRON D, STACHOWIAK A,
LOEWENSTEIN O, et al. Long-term efficacy and safety of oxycodone-naloxone
prolonged-release formulation (up to 180/90 mg daily) - results of the
open-label extension phase of a phase III multicenter, multiple-dose,
randomized, controlled study[J/OL]. European Journal of Pain (london, England),
2017, 21(9): 1485-1494. DOI:10.1002/ejp.1050.
[13] AHMEDZAI S H, NAUCK F,
BAR-SELA G, et al. A randomized, double-blind, active-controlled, double-dummy,
parallel-group study to determine the safety and efficacy of oxycodone/naloxone
prolonged-release tablets in patients with moderate/severe, chronic cancer
pain[J/OL]. Palliative Medicine, 2012, 26(1): 50-60.
DOI:10.1177/0269216311418869.
[14] AHMEDZAI S H, LEPPERT W,
JANECKI M, et al. Long-term safety and efficacy of oxycodone/naloxone
prolonged-release tablets in patients with moderate-to-severe chronic cancer
pain[J/OL]. Supportive Care in Cancer, 2015, 23(3): 823-830.
DOI:10.1007/s00520-014-2435-5.
[15] SIMPSON K, LEYENDECKER P,
HOPP M, et al. Fixed-ratio combination oxycodone/naloxone compared with
oxycodone alone for the relief of opioid-induced constipation in
moderate-to-severe noncancer pain[J/OL]. Current Medical Research and Opinion,
2008, 24(12): 3503-3512. DOI:10.1185/03007990802584454.
[16] LÖWENSTEIN O, LEYENDECKER
P, HOPP M, et al. Combined prolonged-release oxycodone and naloxone improves
bowel function in patients receiving opioids for moderate-to-severe
non-malignant chronic pain: A randomised controlled trial[J/OL]. Expert Opinion
on Pharmacotherapy, 2009, 10(4): 531-543. DOI:10.1517/14656560902796798.
[17] LÖWENSTEIN O, LEYENDECKER
P, LUX E A, et al. Efficacy and safety of combined prolonged-release oxycodone
and naloxone in the management of moderate/severe chronic non-malignant pain:
Results of a prospectively designed pooled analysis of two randomised,
double-blind clinical trials[J/OL]. BMC Clinical Pharmacology, 2010, 10: 12.
DOI:10.1186/1472-6904-10-12.
[18] BLAGDEN M, HAFER J, DUERR
H, et al. Long-term evaluation of combined prolonged-release oxycodone and
naloxone in patients with moderate-to-severe chronic pain: Pooled analysis of
extension phases of two phase III trials[J/OL]. Neurogastroenterology and
Motility, 2014, 26(12): 1792-1801. DOI:10.1111/nmo.12463.
[19] KOOPMANS G, SIMPSON K, DE
ANDRÉS J, et al. Fixed ratio (2:1) prolonged-release oxycodone/naloxone
combination improves bowel function in patients with moderate-to-severe pain
and opioid-induced constipation refractory to at least two classes of
laxatives[J/OL]. Current Medical Research and Opinion, 2014, 30(11): 2389-2396.
DOI:10.1185/03007995.2014.971355.
[20] NATIONAL COMPREHENSIVE
CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Adult Cancer
Pain Version 2.2024[EB/OL]. (2024-03-11) [2024-06-19].
https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf
[21] FALLON M, GIUSTI R, AIELLI
F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice
Guidelines[J]. Ann Oncol, 2018,29(Suppl 4):iv166-iv191.
[22] LARKIN PJ, CHERNY NI, LA
CARPIA D, et al. Diagnosis, assessment and management of constipation in
advanced cancer: ESMO Clinical Practice Guidelines[J]. Ann Oncol. 2018 Oct
1;29(Suppl 4):iv111-iv125.
[23] MÜLLER-LISSNER S, BASSOTTI
G, COFFIN B, et al. Opioid-Induced Constipation and Bowel Dysfunction: A
Clinical Guideline[J]. Pain Med. 2017 Oct 1;18(10):1837-1863.
[24] 中国慢性癌症相关性疼痛诊疗指南制订专家组,中国老年保健协会疼痛病学分会. 中国慢性癌症相关性疼痛诊疗指南(2024版)[J]. 中华疼痛学杂志,2024,20(05):646-664.
[25] 中华医学会消化病学分会胃肠动力学组,中华医学会消化病学分会功能性胃肠病协作组.中国慢性便秘专家共识意见(2019,广州)[J].中华消化杂志,2019,39(9): 577-598.